RxDoctor Payments Data

David Kaplowitz, MD

Internal Medicine · New York, NYNPI 1083670103

Payments from drug & device makers

$15,276in general payments, 2019–2025

Across 277 payments — averaging $55.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$2K
  • Amgen$2K
  • Boehringer Ingelheim$2K
  • AbbVie$1K
  • Nevro Corp.$834
  • AstraZeneca$691
  • plus $7K from 35 others

What the payments were for

  • Food & beverage$15,244100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,276 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$51,033
Medicare patients
80
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$45,422
JardianceEmpagliflozin18$25,999
OzempicSemaglutide15$22,325
XareltoRivaroxaban19$21,759
Metformin Er GastricMetformin Hcl14$9,962
Ezetimibe88$1,946
Rosuvastatin Calcium144$1,609
Mesalamine13$1,060
Losartan Potassium72$696
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide15$476
Metoprolol Succinate36$462
Levothyroxine Sodium27$444
Albuterol Sulfate HfaAlbuterol Sulfate12$437
Tamsulosin Hcl30$406
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide22$378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$122$45,42238 claims
Boehringer IngelheimJardiance$1,691$25,99918 claims
Novo NordiskOzempic$246$22,32515 claims
Johnson & JohnsonXarelto$97$21,75919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →